Qube Research & Technologies (QRT)’s Beam Therapeutics BEAM Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.9M	Buy	1,084,768 +685,109	+171%	+$19M	0.03%	731
2025 Q4	$11.1M	Buy	399,659 +329,228	+467%	+$8.4M	0.01%	1280
2025 Q3	$1.71M	Sell	70,431 -523,384	-88%	-$10.4M	﹤0.01%	2303
2025 Q2	$10.1M	Buy	+593,815	New	+$10.3M	0.01%	1279
2024 Q3	–	Sell	-102,359	Closed	-$2.4M	–	3323
2024 Q2	$2.4M	Buy	102,359 +4,304	+4%	+$106K	﹤0.01%	1549
2024 Q1	$3.24M	Buy	+98,055	New	+$3.05M	0.01%	1476
2023 Q2	–	Sell	-114,568	Closed	-$3.51M	–	2402
2023 Q1	$3.51M	Buy	+114,568	New	+$4.52M	0.02%	774
2022 Q2	–	Sell	-18,773	Closed	-$1.08M	–	2502
2022 Q1	$1.08M	Buy	+18,773	New	+$1.23M	0.01%	1136
2021 Q4	–	Sell	-4,315	Closed	-$375K	–	2527
2021 Q3	$375K	Buy	4,315 +1,640	+61%	+$165K	﹤0.01%	1376
2021 Q2	$344K	Sell	2,675 -1,311	-33%	-$104K	﹤0.01%	1496
2021 Q1	$319K	Buy	+3,986	New	+$379K	0.01%	1424

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Qube Research & Technologies (QRT)'s BEAM Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Beam Therapeutics (BEAM) stake by 171% in Q1 2026, buying an estimated $19M and bringing the position to 1,084,768 shares worth $25.9M. The position accounts for 0.03% of the portfolio, ranked #731.

Qube Research & Technologies (QRT) first reported a position in BEAM in Q1 2021 and has held it in 11 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

Qube Research & Technologies (QRT) held 1,084,768 shares of Beam Therapeutics worth $25.9M as of Q1 2026.
Qube Research & Technologies (QRT) bought 685,109 Beam Therapeutics shares in Q1 2026, an estimated $19M.
Beam Therapeutics made up 0.03% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #731 holding.
Qube Research & Technologies (QRT) first reported a position in Beam Therapeutics in Q1 2021 and has held it in 11 quarters since.
251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.